Memantine – Mechanism of Action | Psychopharmacology | Clinical Application
Memantine is a low-affinity voltage-dependent non-competitive NMDA receptor antagonist that is approved for treating moderate-to-severe Alzheimer’s disease (AD). [Reisberg et al 2003]
Memantine is a primary aliphatic amine with a three-ring structure that binds to the magnesium cation channel of the NMDA receptor.
- Memantine is available as an oral solution, a tablet, and an extended-release capsule.
- Memantine can be prescribed independently or with an acetylcholinesterase inhibitor such as donepezil, rivastigmine, or galantamine. [Allgaier and Allgaier 2014]
Kulkarni, J., Thomas, N., Hudaib, A. R., Gavrilidis, E., Grigg, J., Tan, R., … & Gurvich, C. (2018). Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial. CNS drugs, 32(2), 179-187.